Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Antitumor activity of interleukin-18 against the murine T-cell leukemia/lymphoma EL-4 in syngeneic mice.

Akamatsu S, Arai N, Hanaya T, Arai S, Tanimoto T, Fujii M, Kohno K, Micallef MJ, Ikeda M, Kurimoto M.

J Immunother. 2002 Mar-Apr;25 Suppl 1:S28-34.

PMID:
12048348
2.

In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites.

Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Kurimoto M.

Cancer Immunol Immunother. 1997 Jan;43(6):361-7.

PMID:
9067408
3.

Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK.

J Exp Med. 1993 Oct 1;178(4):1223-30.

5.

In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.

Baxevanis CN, Gritzapis AD, Papamichail M.

J Immunol. 2003 Sep 15;171(6):2953-9.

7.

Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12.

Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK.

J Immunother Emphasis Tumor Immunol. 1995 Feb;17(2):71-7.

PMID:
7647958
8.

IL-28 elicits antitumor responses against murine fibrosarcoma.

Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, Iwakura Y, Aiba S, Yamaya M.

J Immunol. 2007 Apr 15;178(8):5086-98.

9.

Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer.

Kundu N, Beaty TL, Jackson MJ, Fulton AM.

J Natl Cancer Inst. 1996 Apr 17;88(8):536-41.

PMID:
8606382
10.

Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.

Chang CY, Lee J, Kim EY, Park HJ, Kwon CH, Joh JW, Kim SJ.

BMC Cancer. 2007 May 23;7:87.

11.
12.
13.
14.

Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice.

Iwasaki T, Yamashita K, Tsujimura T, Kashiwamura S, Tsutsui H, Kaisho T, Sugihara A, Yamada N, Mukai M, Yoneda T, Okamura H, Akedo H, Terada N.

J Immunother. 2002 Mar-Apr;25 Suppl 1:S52-60.

PMID:
12048351
15.

Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.

Wei H, Zheng X, Lou D, Zhang L, Zhang R, Sun R, Tian Z.

Mol Immunol. 2005 May;42(9):1023-31. Epub 2004 Nov 23.

PMID:
15829292
16.

In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma.

Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS.

Clin Exp Metastasis. 1996 May;14(3):219-29.

PMID:
8674276
17.

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S.

J Immunol. 2004 Feb 1;172(3):1540-7.

18.

[Preparation of mB7.1-GPI and SEA-TM dual-anchored tumor cell vaccine and its antitumor effect].

Yi PY, Yu H, Ma WX, Wang QQ, Huang CX, Li JZ.

Zhonghua Yi Xue Za Zhi. 2004 Sep 17;84(18):1567-71. Chinese.

PMID:
15500723
20.

Potent antitumor activity of interleukin-27.

Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T.

Cancer Res. 2004 Feb 1;64(3):1152-6.

Supplemental Content

Support Center